Pirprofen

Summary

Pirprofen (CHEMBL188952) is an approved small molecule (ATC M01AE08); indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AE08
• Indications: 1 condition
• Chemistry: 251.71 Da · C13H14ClNO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL188952
Name	Pirprofen
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	35935
ATC	M01AE08
Molecular formula	C13H14ClNO2
Molecular weight	251.71
InChIKey	PIDSZXPFGCURGN-UHFFFAOYSA-N

SMILES: CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O

IUPAC name: 2-[3-chloro-4-(2,5-dihydropyrrol-1-yl)phenyl]propanoic acid

Also known as: Pirprofen, Pirprofene, Pirprofeno, Racemic pirprofen, Rangasil 400, Rengasil, Seflenyl, SU 21524, SU-21524, pirprofen, PIRPROFEN, PIRPROFENE

Patent coverage: 4,445 distinct patent families (17,635 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 17,634 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Muscarinic acetylcholine receptor M1, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS1	7.49	AC50	32.5	nM	CHEMBL_ACT_25205453
PTGS1	6.94	AC50	115.2	nM	CHEMBL_ACT_25206384

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).